Beneventi et Case series N=135 female survivors treated for Blood samples were collected in the early follicular Inhibin B Gen II ELISA Correlation: al. () childhood malignant and non-malignant phase in patients with spontaneous menstrual Spearman’s Quality: Low risk According to manufacturer’s instructions diseases and patients who had received cycles, and in withdrawal bleeding in patients rank Italy of bias BMT for thalassaemia major or sickle cell treated with oral contraceptives or HRT. correlation anaemia. test AMH Gen II ELISA 92 (68.1%) diagnosed before menarche According to manufacturer’s instructions. 43 (31.85%) diagnosed after menarche Median age at enrolment = 19 years (IQR 16–21) Median age at start of treatment = 10 years (IQR 6–16) Median time since treatment = 9 years (IQR 6–12). Biacchiardi Case series N=43 normo-ovulatory women aged 18–42 Blood samples were drawn during the early AFC TVUS Correlation: et al. () years who were affected by one or more follicular phase (day 3) of the month in which Pearson’s Quality: Low risk Transvaginal ultrasound examination was ovarian endometriomas surgery was scheduled. Sera were frozen at -20°C bivariate Italy of bias performed in the early follicular phase in order to for subsequent centralised testing correlation Mean age = 34.2 ± 5.4 years estimate the AFC. AFC was determined by test EIA AMH/MIS assay counting the follicles >3 mm diameter that were n=7 ASRM stage 2 visible through a complete scanning of both Intra-assay and inter-assay CoV of 12.3% and n=26 ASRM stage 3 ovaries. In order to avoid any operator-linked bias, 14.2%, respectively. n=10 ASRM stage 4 all ultrasound examinations were done by the same investigators using the same equipment.
Beneventi et al. () Italy Case series Quality: Low risk of bias N=135 female survivors treated for childhood malignant and non-malignant diseases and patients who had received BMT for thalassaemia major or sickle cell anaemia. 92 (68.1%) diagnosed before menarche 43 (31.85%) diagnosed after menarche Median age at enrolment = 19 years (IQR 16–21) Median age at start of treatment = 10 years (IQR 6–16) Median time since treatment = 9 years (IQR 6–12). Blood samples were collected in the early follicular phase in patients with spontaneous menstrual cycles, and in withdrawal bleeding in patients treated with oral contraceptives or HRT. AMH Gen II ELISA According to manufacturer’s instructions. Inhibin B Gen II ELISA According to manufacturer’s instructions Correlation: Spearman’s rank correlation test Biacchiardi et al. () Italy Case series Quality: Low risk of bias N=43 normo-ovulatory women aged 18–42 years who were affected by one or more ovarian endometriomas Mean age = 34.2 ± 5.4 years n=7 ASRM stage 2 n=26 ASRM stage 3 n=10 ASRM stage 4 Blood samples were drawn during the early follicular phase (day 3) of the month in which surgery was scheduled. Sera were frozen at -20°C for subsequent centralised testing EIA AMH/MIS assay Intra-assay and inter-assay CoV of 12.3% and 14.2%, respectively. AFC TVUS Transvaginal ultrasound examination was performed in the early follicular phase in order to estimate the AFC. AFC was determined by counting the follicles >3 mm diameter that were visible through a complete scanning of both ovaries. In order to avoid any operator-linked bias, all ultrasound examinations were done by the same investigators using the same equipment. Correlation: Pearson’s bivariate correlation test
1434-Assessment_Report-Accessible.docx